Breakthrough Clinical Results
23andMe, a genetics-led consumer healthcare company, has received court approval for the sale of substantially all of its assets to TTAM Research Institute, a nonprofit public benefit corporation. The $305 million sale includes the Personal Genome Service (PGS), Research Services, and Lemonaid Health business lines. TTAM, led by 23andMe's co-founder, Anne Wojcicki, aims to continue 23andMe's mission of improving access to and understanding of genomic information for the public good. The transaction is expected to close in the coming weeks, subject to customary closing conditions. All 23andMe customers will be notified of the sale and TTAM commits to upholding existing privacy policies and implementing additional consumer protections.
Key Highlights
- Court approval received for the sale of 23andMe to TTAM Research Institute.
- Sale price is $305 million.
- TTAM is a nonprofit organization committed to advancing human health globally.
- Transaction expected to close in the coming weeks.
Company Mechanism of Action
Mechanisms of Action in 23andMe Holding Co.'s Drug Development
Based on the provided context, there is insufficient information about the specific mechanisms of action, molecular targets, signaling pathways, or receptor interactions involved in 23andMe Holding Co.'s drug discovery pipeline, pharmaceutical partnerships, or genomic research programs.
The context does not contain details about: - Any specific drugs developed by 23andMe - Therapeutic candidates in their pipeline - Molecular targets of their compounds - Signaling pathways involved in their therapeutics - Receptor interactions of their investigational agents - Pharmacological mechanisms utilized in their drug development
Without this information in the provided context, a comprehensive answer about the mechanisms of action of drugs from 23andMe Holding Co. cannot be formulated.
Company drugs in pipeline
23andMe Holding Co.'s Drug Pipeline
Based on the available information, there is no specific data regarding drug candidates being developed by 23andMe Holding Co. The context does not contain any information about 23andMe Holding Co.'s pharmaceutical development pipeline or any pathological conditions, disorders, or diseases being addressed by their drug candidates.
The review of all input materials indicates that 23andMe Holding Co. is not mentioned in any of the provided context, and consequently, there is no information about their therapeutic indications or disease targets in pharmaceutical development.